| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CMRF35-like molecule 1, CLM-1, CD300 antigen-like family member F, Immune receptor expressed on myeloid cells 1, IREM-1, Immunoglobulin superfamily member 13, IgSF13, NK inhibitory receptor, CD300f, CD300LF, CD300F, CLM1, IGSF13, IREM1, NKIR |
| Entrez GeneID | 146722 |
| WB Predicted band size | 32.3kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CLM1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 56-84 amino acids from the N-terminal region of human CLM1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是基于CLM1(N端抗体)相关研究的模拟参考文献示例(实际文献需通过学术数据库验证)：
1. **文献名称**：Characterization of CLM1 N-terminal antibody in immune cell signaling
**作者**：Sato K, et al.
**摘要**：本研究开发了针对CLM1蛋白N端的特异性抗体，验证了其在人外周血单核细胞中的表达，并发现CLM1通过N端结构域与TLR4受体相互作用，调控NF-κB炎症通路。
2. **文献名称**：CLM1 extracellular domain mediates endothelial adhesion in atherosclerosis
**作者**：Zhang Y, et al.
**摘要**：通过N端抗体阻断实验，证实CLM1的N端区域参与血管内皮细胞黏附分子(VCAM-1)的激活，该抗体在小鼠动脉粥样硬化模型中显著减少斑块形成。
3. **文献名称**：Development of monoclonal antibodies against CLM1 for cancer diagnostics
**作者**：Müller R, et al.
**摘要**：报道一种高亲和力抗CLM1 N端单克隆抗体的制备，该抗体在结直肠癌组织切片中显示出高特异性染色，提示CLM1可作为肿瘤标志物。
4. **文献名称**：Structural insights into CLM1 N-terminal domain by cryo-EM
**作者**：Chen L, et al.
**摘要**：利用N端抗体辅助的冷冻电镜技术解析CLM1蛋白N端结构，揭示其与配体结合的关键氨基酸位点，为靶向药物设计提供依据。
---
**注意**：以上为模拟内容，实际文献需通过PubMed/Google Scholar检索确认。建议使用关键词"CLM1 N-terminal antibody"或结合UniProt数据库(如查询CLM1的官方基因名)进行精准查找。
The CLM1 (N-term) antibody is designed to target the N-terminal region of the CKLF-like MARVEL transmembrane domain-containing protein 1 (CLM1/CMTM1), a member of the MARVEL domain protein family implicated in membrane-associated processes such as cell adhesion, trafficking, or signaling. This antibody is typically generated in immunized hosts (e.g., rabbits or mice) using synthetic peptides corresponding to the N-terminal sequence of human CLM1. followed by affinity purification to ensure specificity. It is widely used in applications like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) to detect endogenous CLM1 expression in human, mouse, or rat tissues and cell lines.
CLM1 is hypothesized to play roles in immune regulation, tumorigenesis, and cellular differentiation, with studies linking its expression to cancers and immune disorders. The N-terminal region may mediate protein-protein interactions or modulate intracellular signaling pathways. Validation of the antibody often includes detection of a band around 20-25 kDa in WB, consistent with CLM1's predicted molecular weight. Researchers should optimize dilution ratios (e.g., 1:500–1:2000 for WB) and consider cross-reactivity with homologous proteins. Storage conditions typically involve aliquoting in PBS with glycerol at -20°C to preserve stability. This tool aids in exploring CLM1's biological functions and its potential as a therapeutic or diagnostic target.
×
